A phase 1, first-in-human study of ¹⁸F-GP1 positron emission tomography for imaging acute arterial thrombosis.

ABSTRACT:

Background

¹⁸F-GP1 is a novel positron emission tomography (PET) tracer that targets glycoprotein IIb/IIIa receptors on activated platelets. The study objective was to explore the feasibility of directly imaging acute arterial thrombosis (AAT) with ¹⁸F-GP1 PET/computed tomography (PET/CT) and to quantitatively assess ¹⁸F-GP1 uptake. Safety, biodistribution, pharmacokinetics and metabolism were also evaluated.

Methods

Adult patients who had signs or symptoms of AAT or had recently undergone arterial intervention or surgery within 14 days prior to ¹⁸F-GP1 PET/CT were eligible for inclusion. The AAT focus was demonstrated by conventional imaging within the 5 days prior to ¹⁸F-GP1 administration. Whole-body dynamic ^18</

SUBMITTER: Chae SY 

PROVIDER: S-EPMC6323046 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature